Company
Therapeutic Areas
Our Pipeline
News
Careers
Contact Us
Select Year
2026
2025
2024
2023
2022
2026.01.02
NeuShen Therapeutics Announces FDA Clearance of IND Application for a Phase 2 Clinical Trial of NS-136 in Agitation in Alzheimer’s Disease (AAD)
2025.11.19
NeuShen Therapeutics Announces First Patient Dosed in Phase 2 Clinical Trial of NS-136 for Schizophrenia
2025.09.28
NeuShen Therapeutics to Present at Neuroscience 2025
2025.06.04
NeuShen Therapeutics to Attend Global Biopharma Leadership Forum 2025
2024.05.28
An Interview with CEO Dr. Joan Shen: Starting a CNS Venture in an Economic Downturn
2024.04.30
NeuShen Therapeutics Initiates First-in-Human Trial of NS-136, a Novel Selective M4 Receptor Positive Allosteric Modulator for the Treatment of Schizophrenia
2024.04.18
NeuShen Therapeutics Announces Four Presentations at the 27th ASGCT Annual Meeting
2024.03.11
NeuShen Therapeutics Granted NMPA-CDE IND Approval for Highly Selective KCNQ2/3 Activator
2023.12.27
NeuShen Therapeutics Announces NMPA-CDE Acceptance of IND Application for Highly Selective KCNQ2/3 Activator
2023.10.24
NeuShen Therapeutics-UMass Chan ALS Program to Present Pre-Clinical Data at ESGCT 2023
About Us
Mission & Culture
Leadership Team
Depression
Schizophrenia
Neurological Disorders
Pipeline
Clinical Trials
Publications
Copyright © 2025 NeuShen Therapeutics, Inc. All rights reserved.
